Compare Incyte Corporation (INCY) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Mongodb Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Mongodb Inc trades at $309.71 (market cap $26.01B). The key difference: Incyte Corporation and Mongodb Inc are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| INCY | MDB | |
|---|---|---|
Market Cap | $23.11B | $26.01B |
Sector | Health | Technology |
52-Week High | $118.52 | $440.25 |
52-Week Low | $67.38 | $201.08 |
Enterprise Value | $19.13B | $23.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MongoDB (MDB) trades at $324.44, up 3.88% today, with strong analyst support (82% buy ratings) and a $400.39 consensus price target. The stock shows bearish technical signals but has consistently beaten earnings expectations, with Q1 2026 EPS of $1.32 surpassing the $1.19 estimate. Revenue growth remains robust at $2.01B for 2025, though profitability challenges persist with a negative net margin of -1.12%.
MDB presents a growth investment opportunity with accelerating revenue and improving margins, but faces execution risks and competitive pressures. The stock's premium valuation (P/S 9.77) requires sustained high growth, while negative cash flow and ongoing profitability concerns warrant caution despite Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
